Therapeutic compositions for bone repair
US-9387250-B2 · Jul 12, 2016 · US
US9782432B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9782432-B2 |
| Application number | US-201514973519-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 17, 2015 |
| Priority date | Oct 25, 2012 |
| Publication date | Oct 10, 2017 |
| Grant date | Oct 10, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Certain embodiments of the invention provide a copolymer having a backbone, wherein the backbone comprises a) one or more units that comprise a group that will yield a biologically active agent upon hydrolysis of the backbone; and b) one or more units of formula (II): wherein y is 1 or more. Other embodiments of the invention provide a therapeutic method for treating a wound in an animal comprising administering to an animal in need of such therapy, an effective amount of a copolymer as described herein.
Opening claim text (preview).
What is claimed is: 1. A therapeutic method for treating a wound, preventing fibrous adhesions at a wound site and/or providing localized analgesia at a wound site in an animal comprising administering to an animal in need of such therapy an effective amount of a copolymer having a backbone, wherein the backbone comprises a) one or more polyanhydride units that comprise a group that will yield a biologically active agent upon hydrolysis of the backbone; and b) one or more units of formula (II): wherein y is 5 to 15. 2. The method of claim 1 , wherein the polyanhydride comprises one or more units of formula (I) in the backbone: —C(═O)R 1 -A-L-A-R 1 C(═O)—O— (I) wherein each R 1 is a group that will provide a biologically active agent upon hydrolysis of the polymer; each A is independently an ester or an amide linkage; and each L is independently a linker molecule. 3. The method of claim 2 , wherein A is independently an ester linkage. 4. The method of claim 2 , wherein L is a divalent, branched or unbranched, saturated or unsaturated, hydrocarbon chain, having from 1 to 25 carbon atoms, wherein one or more of the carbon atoms is optionally replaced by (—O—), (—NR—) or phenylene, and wherein the chain is optionally substituted on carbon with one or more substituents selected from the group consisting of (C 1 -C 6 )alkoxy, (C 3 -C 6 )cycloalkyl, (C 1 -C 6 )alkanoyl, (C 1 -C 6 )alkanoyloxy, (C 1 -C 6 )alkoxycarbonyl, (C 1 -C 6 )alkylthio, azido, cyano, nitro, halo, hydroxy, oxo, carboxy, aryl, aryloxy, heteroaryl, and heteroaryloxy, wherein each R is independently selected from H or (C 1 -C 6 )alkyl. 5. The method of claim 2 , wherein L is —CH 2 CH 2 CH 2 CH 2 — or —CH 2 C(Et) 2 CH 2 —. 6. The method of claim 1 , wherein the biologically active agent is an antimicrobial, anti-inflammatory, antioxidant, analgesic, anticoagulant or fibrinolytic. 7. The method of claim 6 , wherein the biologically active agent is an anti-inflammatory agent. 8. The method of claim 7 , wherein the anti-inflammatory agent is salicylic acid. 9. The method of claim 1 , wherein the ratio of the a) one or more units that comprise a group that will yield a biologically active agent upon hydrolysis of the backbone to the b) one or more units of formula (II), ranges from between about 5:1 to about 1:5. 10. The method of claim 9 , wherein the ratio ranges from 2:1 to 1:2. 11. The method of claim 10 , wherein the ratio is 1:1 or 2:1. 12. The method of claim 1 , wherein the copolymer comprises one or more units of formula (III): wherein each L is independently a linker molecule; x is 5 or more; y is 5 to 15; and z is 5 or more. 13. The method of claim 1 , wherein the copolymer has an average molecular weight of about 10,000 daltons to about 30,000 daltons. 14. The method of claim 1 , wherein the copolymer further comprises a second biologically active agent dispersed in the matrix of the copolymer. 15. The method of claim 1 , wherein a pharmaceutical composition comprising the copolymer and a pharmaceutically acceptable carrier is administered to the animal in need of such therapy. 16. A therapeutic method for preventing fibrous adhesions at a wound site in an animal comprising administering to an animal in need of such therapy an effective amount of a copolymer having a backbone, wherein the backbone comprises a) one or more polyanhydride units that comprise a group that will yield a biologically active agent upon hydrolysis of the backbone; and b) one or more units of formula (II): wherein y is 5 to 15. 17. A therapeutic method for preventing fibrous adhesions at a wound site in an animal comprising administering to an animal in need of such therapy an effective amount of a copolymer comprising one or more units of formula (IIIa): wherein x is 5 or more; y is 5 to 15; and z is 5 or more.
Polymers containing oxygen · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.